Multiple Myeloma Coverage from Every Angle

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

By: Anna Nowogrodzki
Posted: Friday, April 2, 2021

Patients with relapsed or refractory multiple myeloma experienced similar or improved health-related quality of life on treatment with daratumumab, bortezomib, and dexamethasone compared with bortezomib and dexamethasone alone, according to patient-reported outcomes from the phase III CASTOR trial. Vania Hungria, MD, PhD, of Santa Casa Medical School,São Paulo, Brazil, and colleagues published their findings in the British Journal of Haematology.

“These results complement the significant clinical benefits observed with daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma and support its use in this patient population,” the authors wrote.

The trial enrolled 498 patients with relapsed or refractory multiple myeloma, randomly assigned to receive either daratumumab, bortezomib, and dexamethasone (251 patients) or bortezomib and dexamethasone alone (247 patients). Previously reported from the CASTOR trial were the progression-free survival data, illustrating a benefit with the triplet regimen over the doublet in this patient population. In this article, the authors focused on evaluating patient-reported outcomes using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30‐item and the EuroQol 5‐dimensional descriptive system questionnaire.

The mean changes from baseline for global health status, functioning, and symptoms were similar between the two treatment groups. The changes were also fairly minimal and did not exceed 10 points on the 30-item questionnaire for either treatment. For the first eight cycles of therapy, patients’ health‐related quality of life was unchanged. After 8 weeks, patients who received daratumumab reported an improvement in global health status and pain. Of note, the trial was an open-label design, which may have affected patients’ self-reported outcomes.

Disclosure: The study authors’ disclosures are found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.